| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kenya | 88 | 2023 | 685 | 3.670 |
Why?
|
| Rural Population | 39 | 2018 | 2210 | 1.940 |
Why?
|
| Menstrual Hygiene Products | 6 | 2019 | 18 | 1.660 |
Why?
|
| Tuberculosis | 27 | 2020 | 1912 | 1.640 |
Why?
|
| Rotavirus Infections | 8 | 2016 | 86 | 1.440 |
Why?
|
| Menstruation | 7 | 2019 | 302 | 1.270 |
Why?
|
| Tuberculosis, Pulmonary | 18 | 2015 | 810 | 1.170 |
Why?
|
| Gastroenteritis | 6 | 2014 | 245 | 1.130 |
Why?
|
| Population Surveillance | 22 | 2019 | 2616 | 1.000 |
Why?
|
| Malaria | 14 | 2023 | 1239 | 0.960 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 14 | 2012 | 912 | 0.880 |
Why?
|
| Disease Outbreaks | 15 | 2020 | 1772 | 0.850 |
Why?
|
| Child Mortality | 6 | 2018 | 198 | 0.770 |
Why?
|
| Directly Observed Therapy | 6 | 2008 | 137 | 0.750 |
Why?
|
| Emigration and Immigration | 7 | 2012 | 404 | 0.720 |
Why?
|
| Rotavirus Vaccines | 5 | 2012 | 61 | 0.710 |
Why?
|
| HIV Infections | 38 | 2019 | 16718 | 0.680 |
Why?
|
| Malaria, Falciparum | 10 | 2018 | 1077 | 0.670 |
Why?
|
| Prenatal Care | 6 | 2019 | 1092 | 0.660 |
Why?
|
| Antitubercular Agents | 14 | 2012 | 1320 | 0.660 |
Why?
|
| Diarrhea | 8 | 2020 | 1348 | 0.650 |
Why?
|
| Cause of Death | 11 | 2018 | 3584 | 0.630 |
Why?
|
| Midwifery | 3 | 2018 | 132 | 0.620 |
Why?
|
| Patient Acceptance of Health Care | 12 | 2019 | 3022 | 0.610 |
Why?
|
| Vaccination | 10 | 2019 | 3278 | 0.610 |
Why?
|
| Tuberculin Test | 7 | 2019 | 214 | 0.600 |
Why?
|
| Vaginosis, Bacterial | 3 | 2017 | 128 | 0.590 |
Why?
|
| Pneumococcal Infections | 3 | 2017 | 497 | 0.580 |
Why?
|
| Data Collection | 12 | 2017 | 3341 | 0.560 |
Why?
|
| Communicable Disease Control | 7 | 2013 | 857 | 0.550 |
Why?
|
| Pneumococcal Vaccines | 3 | 2017 | 391 | 0.540 |
Why?
|
| Sexually Transmitted Diseases | 3 | 2016 | 624 | 0.540 |
Why?
|
| Family Characteristics | 5 | 2019 | 1000 | 0.540 |
Why?
|
| India | 23 | 2022 | 2197 | 0.540 |
Why?
|
| AIDS-Related Opportunistic Infections | 6 | 2011 | 657 | 0.520 |
Why?
|
| AIDS Serodiagnosis | 3 | 2013 | 184 | 0.510 |
Why?
|
| Mycobacterium tuberculosis | 16 | 2019 | 1832 | 0.510 |
Why?
|
| Communicable Diseases | 6 | 2014 | 880 | 0.500 |
Why?
|
| Ownership | 2 | 2015 | 332 | 0.490 |
Why?
|
| House Calls | 2 | 2013 | 160 | 0.490 |
Why?
|
| Epidemiologic Research Design | 1 | 2018 | 367 | 0.480 |
Why?
|
| Vaccines, Conjugate | 1 | 2015 | 333 | 0.470 |
Why?
|
| Weather | 1 | 2015 | 228 | 0.460 |
Why?
|
| Hygiene | 3 | 2019 | 98 | 0.460 |
Why?
|
| Politics | 3 | 2010 | 791 | 0.450 |
Why?
|
| Sputum | 8 | 2012 | 476 | 0.450 |
Why?
|
| Demography | 7 | 2014 | 1656 | 0.440 |
Why?
|
| Violence | 2 | 2010 | 909 | 0.430 |
Why?
|
| Adolescent | 75 | 2019 | 85781 | 0.430 |
Why?
|
| Indians, South American | 4 | 1999 | 36 | 0.430 |
Why?
|
| Occupations | 1 | 2015 | 517 | 0.420 |
Why?
|
| Directive Counseling | 2 | 2013 | 166 | 0.420 |
Why?
|
| Anemia | 5 | 2023 | 1506 | 0.420 |
Why?
|
| BCG Vaccine | 4 | 2020 | 369 | 0.410 |
Why?
|
| Abscess | 1 | 2015 | 607 | 0.410 |
Why?
|
| Rural Health Services | 5 | 2013 | 379 | 0.390 |
Why?
|
| Infant | 46 | 2023 | 35136 | 0.390 |
Why?
|
| Scrub Typhus | 2 | 2022 | 4 | 0.390 |
Why?
|
| Mass Screening | 12 | 2015 | 5255 | 0.380 |
Why?
|
| Continuity of Patient Care | 1 | 2018 | 1049 | 0.380 |
Why?
|
| Democracy | 1 | 2010 | 28 | 0.370 |
Why?
|
| Hematologic Tests | 1 | 2011 | 240 | 0.360 |
Why?
|
| Artemisinins | 5 | 2018 | 221 | 0.360 |
Why?
|
| Child, Preschool | 39 | 2023 | 41006 | 0.350 |
Why?
|
| Risk-Taking | 1 | 2015 | 986 | 0.350 |
Why?
|
| Plasmodium falciparum | 10 | 2018 | 1732 | 0.350 |
Why?
|
| Blood Chemical Analysis | 1 | 2011 | 440 | 0.340 |
Why?
|
| Litchi | 3 | 2017 | 3 | 0.340 |
Why?
|
| Prevalence | 28 | 2021 | 15226 | 0.330 |
Why?
|
| Water Supply | 4 | 2018 | 214 | 0.330 |
Why?
|
| Female | 115 | 2022 | 380194 | 0.330 |
Why?
|
| Regional Health Planning | 1 | 2009 | 97 | 0.320 |
Why?
|
| Insecticide-Treated Bednets | 3 | 2016 | 64 | 0.320 |
Why?
|
| Neurotoxicity Syndromes | 3 | 2017 | 290 | 0.320 |
Why?
|
| Health Knowledge, Attitudes, Practice | 12 | 2019 | 3923 | 0.320 |
Why?
|
| Schools | 6 | 2019 | 1433 | 0.320 |
Why?
|
| Humans | 166 | 2023 | 744343 | 0.310 |
Why?
|
| Sanitation | 2 | 2018 | 93 | 0.310 |
Why?
|
| Young Adult | 38 | 2019 | 56430 | 0.310 |
Why?
|
| Administrative Personnel | 1 | 2009 | 187 | 0.300 |
Why?
|
| Antimalarials | 7 | 2018 | 905 | 0.290 |
Why?
|
| Staff Development | 1 | 2009 | 223 | 0.290 |
Why?
|
| Absenteeism | 3 | 2019 | 250 | 0.290 |
Why?
|
| Student Dropouts | 2 | 2016 | 27 | 0.280 |
Why?
|
| Immunization Programs | 4 | 2020 | 260 | 0.280 |
Why?
|
| Autopsy | 5 | 2018 | 1020 | 0.280 |
Why?
|
| Rifampin | 5 | 2009 | 315 | 0.280 |
Why?
|
| Social Class | 2 | 2015 | 1999 | 0.280 |
Why?
|
| Cross Infection | 3 | 2022 | 1416 | 0.280 |
Why?
|
| Home Care Services | 1 | 2013 | 606 | 0.280 |
Why?
|
| Rural Health | 5 | 2016 | 305 | 0.270 |
Why?
|
| Insecticides | 4 | 2016 | 195 | 0.270 |
Why?
|
| Anthrax | 3 | 2019 | 88 | 0.270 |
Why?
|
| Abortion, Spontaneous | 3 | 2016 | 544 | 0.270 |
Why?
|
| Adult | 76 | 2021 | 214055 | 0.270 |
Why?
|
| Mortality | 3 | 2014 | 2864 | 0.270 |
Why?
|
| Infant, Newborn | 22 | 2022 | 25625 | 0.260 |
Why?
|
| Multivariate Analysis | 13 | 2016 | 12245 | 0.260 |
Why?
|
| Operations Research | 1 | 2005 | 23 | 0.260 |
Why?
|
| Betaine | 1 | 2005 | 87 | 0.260 |
Why?
|
| Encephalitis Virus, Japanese | 2 | 2022 | 11 | 0.260 |
Why?
|
| Students, Nursing | 1 | 2005 | 45 | 0.260 |
Why?
|
| Refugees | 2 | 2010 | 511 | 0.260 |
Why?
|
| National Health Programs | 2 | 2007 | 445 | 0.250 |
Why?
|
| Male | 93 | 2022 | 350118 | 0.250 |
Why?
|
| Students | 4 | 2018 | 1654 | 0.250 |
Why?
|
| Menarche | 3 | 2018 | 516 | 0.240 |
Why?
|
| Reference Values | 1 | 2011 | 4982 | 0.230 |
Why?
|
| Preventive Health Services | 1 | 2009 | 575 | 0.230 |
Why?
|
| Pregnancy Complications | 3 | 2016 | 2861 | 0.230 |
Why?
|
| Haemophilus Vaccines | 2 | 2014 | 69 | 0.230 |
Why?
|
| Public Health | 2 | 2008 | 2603 | 0.230 |
Why?
|
| Diphtheria-Tetanus-Pertussis Vaccine | 2 | 2014 | 56 | 0.230 |
Why?
|
| Developing Countries | 9 | 2018 | 2815 | 0.220 |
Why?
|
| Anopheles | 6 | 2018 | 197 | 0.220 |
Why?
|
| Seasons | 7 | 2016 | 1493 | 0.210 |
Why?
|
| Infant Mortality | 4 | 2018 | 754 | 0.210 |
Why?
|
| Vietnam | 6 | 2009 | 408 | 0.210 |
Why?
|
| Diarrhea, Infantile | 2 | 2013 | 109 | 0.210 |
Why?
|
| Mosquito Control | 3 | 2013 | 104 | 0.210 |
Why?
|
| Hepatitis B Vaccines | 2 | 2014 | 194 | 0.210 |
Why?
|
| Fruit | 2 | 2017 | 1142 | 0.200 |
Why?
|
| Chromatography, Thin Layer | 1 | 2001 | 223 | 0.200 |
Why?
|
| Health Services Accessibility | 5 | 2014 | 5137 | 0.200 |
Why?
|
| Cross-Sectional Studies | 16 | 2021 | 25043 | 0.190 |
Why?
|
| Vaccines, Attenuated | 5 | 2014 | 342 | 0.190 |
Why?
|
| Malaria Vaccines | 2 | 2012 | 158 | 0.190 |
Why?
|
| Streptococcus pneumoniae | 2 | 2017 | 714 | 0.190 |
Why?
|
| Bacillus anthracis | 3 | 2019 | 123 | 0.190 |
Why?
|
| Child | 35 | 2023 | 77709 | 0.190 |
Why?
|
| Isoniazid | 2 | 2005 | 274 | 0.190 |
Why?
|
| Hepatitis E | 2 | 2019 | 76 | 0.190 |
Why?
|
| Specimen Handling | 1 | 2005 | 694 | 0.190 |
Why?
|
| Henipavirus Infections | 1 | 2019 | 7 | 0.180 |
Why?
|
| Socioeconomic Factors | 10 | 2016 | 7785 | 0.180 |
Why?
|
| Program Evaluation | 6 | 2014 | 2488 | 0.180 |
Why?
|
| Pyrethrins | 2 | 2016 | 47 | 0.180 |
Why?
|
| Health Surveys | 6 | 2018 | 4037 | 0.180 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 3 | 2021 | 567 | 0.180 |
Why?
|
| Guidelines as Topic | 1 | 2006 | 1405 | 0.180 |
Why?
|
| Colistin | 1 | 2019 | 47 | 0.170 |
Why?
|
| Influenza, Human | 4 | 2017 | 1479 | 0.170 |
Why?
|
| Feasibility Studies | 7 | 2018 | 5078 | 0.170 |
Why?
|
| Livestock | 2 | 2019 | 19 | 0.170 |
Why?
|
| Orientia tsutsugamushi | 1 | 2018 | 3 | 0.170 |
Why?
|
| Malaria, Vivax | 2 | 1999 | 173 | 0.170 |
Why?
|
| Encephalitis, Japanese | 1 | 2019 | 12 | 0.170 |
Why?
|
| Escherichia coli Infections | 2 | 2020 | 532 | 0.170 |
Why?
|
| Anti-Infective Agents | 2 | 2022 | 972 | 0.170 |
Why?
|
| HIV | 5 | 2012 | 1604 | 0.170 |
Why?
|
| Syphilis | 2 | 2019 | 227 | 0.170 |
Why?
|
| Anti-HIV Agents | 7 | 2018 | 4256 | 0.170 |
Why?
|
| Reagent Kits, Diagnostic | 2 | 2011 | 224 | 0.170 |
Why?
|
| Jaundice | 1 | 2019 | 89 | 0.170 |
Why?
|
| International Cooperation | 5 | 2010 | 1420 | 0.170 |
Why?
|
| Risk Factors | 32 | 2019 | 72290 | 0.170 |
Why?
|
| Pneumonia, Ventilator-Associated | 1 | 2022 | 274 | 0.170 |
Why?
|
| Soaps | 1 | 2018 | 28 | 0.160 |
Why?
|
| Skin Diseases, Bacterial | 1 | 2019 | 66 | 0.160 |
Why?
|
| Cost of Illness | 4 | 2015 | 1859 | 0.160 |
Why?
|
| Klebsiella Infections | 1 | 2019 | 138 | 0.160 |
Why?
|
| Pregnancy | 16 | 2019 | 29144 | 0.160 |
Why?
|
| Hepatitis E virus | 1 | 2019 | 71 | 0.160 |
Why?
|
| Time Factors | 13 | 2018 | 40075 | 0.160 |
Why?
|
| Cryptosporidium | 1 | 2018 | 45 | 0.160 |
Why?
|
| Microbial Sensitivity Tests | 7 | 2017 | 1877 | 0.160 |
Why?
|
| Pregnancy Complications, Infectious | 4 | 2019 | 2026 | 0.160 |
Why?
|
| Cryptosporidiosis | 1 | 2018 | 60 | 0.160 |
Why?
|
| DNA, Protozoan | 2 | 1999 | 237 | 0.150 |
Why?
|
| Terminology as Topic | 1 | 2005 | 1547 | 0.150 |
Why?
|
| Floods | 1 | 2018 | 42 | 0.150 |
Why?
|
| Middle Aged | 48 | 2019 | 213383 | 0.150 |
Why?
|
| Klebsiella pneumoniae | 1 | 2019 | 251 | 0.150 |
Why?
|
| Men | 1 | 2017 | 63 | 0.150 |
Why?
|
| Tuberculosis Vaccines | 1 | 2018 | 50 | 0.150 |
Why?
|
| Infectious Disease Transmission, Vertical | 2 | 2014 | 1320 | 0.150 |
Why?
|
| Africa | 6 | 2020 | 673 | 0.150 |
Why?
|
| Lost to Follow-Up | 1 | 2018 | 105 | 0.150 |
Why?
|
| Immunization Schedule | 3 | 2012 | 221 | 0.150 |
Why?
|
| Dengue Virus | 1 | 2019 | 204 | 0.140 |
Why?
|
| Case-Control Studies | 14 | 2020 | 21746 | 0.140 |
Why?
|
| Pregnancy Complications, Hematologic | 1 | 2018 | 183 | 0.140 |
Why?
|
| Urinary Tract Infections | 1 | 2022 | 788 | 0.140 |
Why?
|
| Measles Vaccine | 1 | 2016 | 76 | 0.140 |
Why?
|
| Mothers | 2 | 2018 | 2165 | 0.130 |
Why?
|
| Perception | 4 | 2017 | 1198 | 0.130 |
Why?
|
| Sulfadoxine | 1 | 2015 | 49 | 0.130 |
Why?
|
| Pregnancy Complications, Parasitic | 1 | 2015 | 54 | 0.130 |
Why?
|
| Kyasanur Forest Disease | 1 | 2015 | 1 | 0.130 |
Why?
|
| Pyrimethamine | 1 | 2015 | 97 | 0.130 |
Why?
|
| Incidence | 11 | 2019 | 20947 | 0.130 |
Why?
|
| Hepatitis, Viral, Human | 1 | 2015 | 138 | 0.130 |
Why?
|
| Polymerase Chain Reaction | 3 | 2009 | 6171 | 0.130 |
Why?
|
| Enteritis | 1 | 2016 | 165 | 0.120 |
Why?
|
| HIV Antibodies | 2 | 2012 | 1322 | 0.120 |
Why?
|
| Health Facilities | 2 | 2018 | 573 | 0.120 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2021 | 687 | 0.120 |
Why?
|
| Staphylococcal Infections | 2 | 2021 | 1400 | 0.120 |
Why?
|
| Adaptive Immunity | 1 | 2019 | 713 | 0.120 |
Why?
|
| Guilt | 1 | 2014 | 95 | 0.120 |
Why?
|
| Sex Factors | 4 | 2013 | 10397 | 0.120 |
Why?
|
| Perinatal Care | 1 | 2016 | 227 | 0.120 |
Why?
|
| Placebos | 4 | 2012 | 1676 | 0.120 |
Why?
|
| Feces | 5 | 2019 | 1401 | 0.120 |
Why?
|
| Quinolines | 2 | 2018 | 732 | 0.120 |
Why?
|
| Insect Vectors | 2 | 2012 | 134 | 0.120 |
Why?
|
| Measles | 1 | 2016 | 168 | 0.120 |
Why?
|
| Child Health Services | 2 | 2011 | 667 | 0.120 |
Why?
|
| Venezuela | 3 | 1999 | 73 | 0.120 |
Why?
|
| Disease Notification | 3 | 2012 | 97 | 0.120 |
Why?
|
| Pilot Projects | 6 | 2018 | 8324 | 0.120 |
Why?
|
| Intention | 1 | 2016 | 341 | 0.120 |
Why?
|
| Occupational Exposure | 4 | 2005 | 1796 | 0.120 |
Why?
|
| Neonatal Screening | 1 | 2018 | 591 | 0.120 |
Why?
|
| Paternal Behavior | 1 | 2013 | 32 | 0.110 |
Why?
|
| Hookworm Infections | 1 | 2012 | 13 | 0.110 |
Why?
|
| Asia | 4 | 2014 | 610 | 0.110 |
Why?
|
| Cambodia | 3 | 2008 | 191 | 0.110 |
Why?
|
| Vaginal Smears | 1 | 2016 | 511 | 0.110 |
Why?
|
| Trichuriasis | 1 | 2012 | 24 | 0.110 |
Why?
|
| Age Distribution | 6 | 2014 | 2902 | 0.110 |
Why?
|
| Mass Chest X-Ray | 2 | 2012 | 16 | 0.110 |
Why?
|
| Focus Groups | 5 | 2015 | 1321 | 0.110 |
Why?
|
| Caregivers | 3 | 2014 | 2094 | 0.110 |
Why?
|
| Rotavirus | 4 | 2016 | 109 | 0.110 |
Why?
|
| Antibiotics, Antitubercular | 3 | 2009 | 104 | 0.110 |
Why?
|
| Schistosomiasis | 1 | 2012 | 62 | 0.110 |
Why?
|
| Tennessee | 2 | 2012 | 117 | 0.110 |
Why?
|
| Postal Service | 2 | 2002 | 96 | 0.110 |
Why?
|
| Public Sector | 3 | 2019 | 265 | 0.110 |
Why?
|
| Anthelmintics | 1 | 2012 | 62 | 0.110 |
Why?
|
| Students, Medical | 1 | 2005 | 1862 | 0.100 |
Why?
|
| Administration, Oral | 4 | 2012 | 3913 | 0.100 |
Why?
|
| Helminthiasis | 1 | 2012 | 66 | 0.100 |
Why?
|
| Ethanolamines | 2 | 2009 | 158 | 0.100 |
Why?
|
| Dominican Republic | 3 | 2007 | 76 | 0.100 |
Why?
|
| Plasmodium malariae | 1 | 2011 | 14 | 0.100 |
Why?
|
| Alcoholic Intoxication | 1 | 2013 | 188 | 0.100 |
Why?
|
| Bioterrorism | 2 | 2002 | 143 | 0.100 |
Why?
|
| Urban Health Services | 1 | 2013 | 179 | 0.100 |
Why?
|
| Needs Assessment | 1 | 2018 | 1147 | 0.100 |
Why?
|
| Medical Errors | 1 | 2000 | 1297 | 0.100 |
Why?
|
| Principal Component Analysis | 1 | 2015 | 940 | 0.100 |
Why?
|
| Rain | 4 | 2012 | 61 | 0.100 |
Why?
|
| Pregnancy Trimester, First | 1 | 2015 | 853 | 0.100 |
Why?
|
| Sensitivity and Specificity | 9 | 2012 | 14722 | 0.100 |
Why?
|
| Sporozoites | 1 | 2011 | 82 | 0.100 |
Why?
|
| World Health Organization | 4 | 2016 | 1318 | 0.100 |
Why?
|
| Social Stigma | 2 | 2014 | 701 | 0.100 |
Why?
|
| Fluorenes | 2 | 2009 | 160 | 0.100 |
Why?
|
| Laboratories | 3 | 2010 | 463 | 0.100 |
Why?
|
| Intussusception | 1 | 2012 | 115 | 0.100 |
Why?
|
| Temperature | 2 | 2015 | 2206 | 0.100 |
Why?
|
| Sexual Partners | 1 | 2015 | 730 | 0.100 |
Why?
|
| Maternal Health Services | 1 | 2016 | 455 | 0.100 |
Why?
|
| Fluid Therapy | 2 | 2013 | 593 | 0.100 |
Why?
|
| Qualitative Research | 5 | 2019 | 2682 | 0.100 |
Why?
|
| Multiple Trauma | 1 | 2013 | 367 | 0.100 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2019 | 941 | 0.090 |
Why?
|
| Multilocus Sequence Typing | 2 | 2021 | 100 | 0.090 |
Why?
|
| Clinical Medicine | 1 | 2012 | 147 | 0.090 |
Why?
|
| Alcohol Drinking | 2 | 2013 | 3966 | 0.090 |
Why?
|
| Registries | 2 | 2007 | 8089 | 0.090 |
Why?
|
| Age Factors | 8 | 2017 | 18370 | 0.090 |
Why?
|
| Colombia | 2 | 2001 | 258 | 0.090 |
Why?
|
| United States | 13 | 2022 | 69872 | 0.090 |
Why?
|
| Family Health | 1 | 2015 | 1282 | 0.090 |
Why?
|
| Delivery, Obstetric | 2 | 2016 | 906 | 0.090 |
Why?
|
| Travel | 1 | 2016 | 788 | 0.090 |
Why?
|
| Labor, Obstetric | 1 | 2013 | 333 | 0.090 |
Why?
|
| Vaccines, Synthetic | 1 | 2012 | 634 | 0.090 |
Why?
|
| Epidemiologic Methods | 1 | 2015 | 1364 | 0.090 |
Why?
|
| Postpartum Hemorrhage | 1 | 2013 | 258 | 0.090 |
Why?
|
| Inhalation Exposure | 2 | 2002 | 443 | 0.090 |
Why?
|
| Reminder Systems | 1 | 2012 | 371 | 0.090 |
Why?
|
| Aged | 25 | 2019 | 163280 | 0.090 |
Why?
|
| Climate Change | 1 | 2015 | 418 | 0.090 |
Why?
|
| Institutional Management Teams | 1 | 2009 | 31 | 0.090 |
Why?
|
| Drug Combinations | 4 | 2015 | 1959 | 0.090 |
Why?
|
| Hospitalization | 6 | 2016 | 10262 | 0.080 |
Why?
|
| Polymorphism, Restriction Fragment Length | 2 | 2000 | 768 | 0.080 |
Why?
|
| Treatment Outcome | 15 | 2015 | 63114 | 0.080 |
Why?
|
| Congenital Abnormalities | 1 | 2013 | 707 | 0.080 |
Why?
|
| Clinical Laboratory Techniques | 2 | 2012 | 738 | 0.080 |
Why?
|
| Lymphocyte Activation | 1 | 2019 | 5524 | 0.080 |
Why?
|
| Sepsis | 1 | 2022 | 2593 | 0.080 |
Why?
|
| Sentinel Surveillance | 2 | 2007 | 281 | 0.080 |
Why?
|
| Models, Statistical | 2 | 2014 | 5102 | 0.080 |
Why?
|
| Immunization | 1 | 2012 | 1256 | 0.080 |
Why?
|
| Papillomavirus Vaccines | 1 | 2014 | 491 | 0.080 |
Why?
|
| Brain Diseases | 1 | 2017 | 1563 | 0.080 |
Why?
|
| Emigrants and Immigrants | 3 | 2012 | 522 | 0.080 |
Why?
|
| Accidents, Traffic | 1 | 2013 | 819 | 0.080 |
Why?
|
| Immunoenzyme Techniques | 1 | 2011 | 1799 | 0.080 |
Why?
|
| Peer Group | 1 | 2013 | 635 | 0.080 |
Why?
|
| Double-Blind Method | 5 | 2012 | 12026 | 0.080 |
Why?
|
| Health Services Research | 3 | 2011 | 1836 | 0.080 |
Why?
|
| Accreditation | 1 | 2010 | 450 | 0.080 |
Why?
|
| Reimbursement, Incentive | 1 | 2012 | 540 | 0.070 |
Why?
|
| Linear Models | 2 | 2016 | 5952 | 0.070 |
Why?
|
| Brazil | 3 | 2007 | 1270 | 0.070 |
Why?
|
| Health Services Needs and Demand | 1 | 2015 | 1411 | 0.070 |
Why?
|
| Healthy People Programs | 1 | 2007 | 53 | 0.070 |
Why?
|
| Ambulatory Care Facilities | 2 | 2015 | 933 | 0.070 |
Why?
|
| Clinical Protocols | 1 | 2013 | 1462 | 0.070 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2019 | 4386 | 0.070 |
Why?
|
| Parasitemia | 3 | 2009 | 174 | 0.070 |
Why?
|
| Drug Resistance, Bacterial | 2 | 2017 | 1035 | 0.070 |
Why?
|
| Treatment Refusal | 2 | 2008 | 421 | 0.070 |
Why?
|
| Patient Satisfaction | 1 | 2019 | 3396 | 0.070 |
Why?
|
| Public-Private Sector Partnerships | 1 | 2007 | 121 | 0.070 |
Why?
|
| Clinical Trials as Topic | 2 | 2020 | 7913 | 0.070 |
Why?
|
| Counseling | 1 | 2014 | 1523 | 0.070 |
Why?
|
| B-Lymphocytes | 1 | 2019 | 4665 | 0.070 |
Why?
|
| Nasopharynx | 3 | 2017 | 379 | 0.070 |
Why?
|
| Women's Health | 1 | 2016 | 2034 | 0.070 |
Why?
|
| Escherichia coli | 1 | 2018 | 4217 | 0.070 |
Why?
|
| Malawi | 1 | 2007 | 282 | 0.070 |
Why?
|
| Follow-Up Studies | 4 | 2018 | 39050 | 0.070 |
Why?
|
| Sexual Behavior | 1 | 2016 | 2057 | 0.070 |
Why?
|
| Benzophenoneidum | 1 | 2005 | 1 | 0.070 |
Why?
|
| Immunoglobulin M | 2 | 2022 | 1537 | 0.070 |
Why?
|
| Academies and Institutes | 1 | 2008 | 317 | 0.070 |
Why?
|
| Delivery of Health Care | 3 | 2012 | 5319 | 0.070 |
Why?
|
| Biological Assay | 1 | 2009 | 652 | 0.070 |
Why?
|
| Accidental Falls | 1 | 2013 | 1062 | 0.070 |
Why?
|
| Dietary Supplements | 1 | 2018 | 3297 | 0.070 |
Why?
|
| Professional Competence | 1 | 2009 | 447 | 0.070 |
Why?
|
| Problem-Based Learning | 1 | 2009 | 361 | 0.060 |
Why?
|
| Organizational Objectives | 1 | 2007 | 438 | 0.060 |
Why?
|
| Drug Therapy, Combination | 5 | 2015 | 6489 | 0.060 |
Why?
|
| Plasmodium vivax | 2 | 1999 | 208 | 0.060 |
Why?
|
| Residence Characteristics | 1 | 2014 | 2050 | 0.060 |
Why?
|
| Rwanda | 1 | 2007 | 703 | 0.060 |
Why?
|
| Private Sector | 2 | 2005 | 392 | 0.060 |
Why?
|
| Vaccines | 1 | 2013 | 822 | 0.060 |
Why?
|
| HIV-1 | 2 | 2012 | 6939 | 0.060 |
Why?
|
| Health Plan Implementation | 1 | 2007 | 352 | 0.060 |
Why?
|
| Logistic Models | 5 | 2018 | 13408 | 0.060 |
Why?
|
| Geography | 2 | 2016 | 669 | 0.060 |
Why?
|
| Predictive Value of Tests | 6 | 2012 | 15076 | 0.060 |
Why?
|
| Personnel, Hospital | 1 | 2005 | 283 | 0.060 |
Why?
|
| Latent Tuberculosis | 2 | 2019 | 225 | 0.060 |
Why?
|
| Risk | 1 | 2015 | 9687 | 0.060 |
Why?
|
| CD4 Lymphocyte Count | 4 | 2013 | 2559 | 0.060 |
Why?
|
| Proportional Hazards Models | 3 | 2012 | 12354 | 0.060 |
Why?
|
| Retrospective Studies | 15 | 2023 | 77449 | 0.060 |
Why?
|
| Anti-Bacterial Agents | 3 | 2018 | 7181 | 0.060 |
Why?
|
| Klebsiella | 1 | 2022 | 48 | 0.050 |
Why?
|
| Anti-Retroviral Agents | 1 | 2012 | 1715 | 0.050 |
Why?
|
| Quality Assurance, Health Care | 2 | 2010 | 2212 | 0.050 |
Why?
|
| Emergency Medicine | 1 | 2012 | 1207 | 0.050 |
Why?
|
| Papillomavirus Infections | 1 | 2014 | 1587 | 0.050 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2014 | 2020 | 0.050 |
Why?
|
| Aged, 80 and over | 8 | 2019 | 57776 | 0.050 |
Why?
|
| Animals | 13 | 2019 | 168757 | 0.050 |
Why?
|
| Health Priorities | 1 | 2005 | 380 | 0.050 |
Why?
|
| Risk Assessment | 4 | 2016 | 23338 | 0.050 |
Why?
|
| Europe, Eastern | 1 | 2001 | 75 | 0.050 |
Why?
|
| Prospective Studies | 7 | 2022 | 53288 | 0.050 |
Why?
|
| Odds Ratio | 3 | 2019 | 9849 | 0.050 |
Why?
|
| Genotype | 2 | 2012 | 12951 | 0.050 |
Why?
|
| Guatemala | 1 | 2021 | 142 | 0.050 |
Why?
|
| Enteropathogenic Escherichia coli | 1 | 2020 | 27 | 0.050 |
Why?
|
| Geographic Information Systems | 2 | 2016 | 281 | 0.050 |
Why?
|
| Intention to Treat Analysis | 2 | 2012 | 426 | 0.050 |
Why?
|
| Staining and Labeling | 1 | 2005 | 1100 | 0.050 |
Why?
|
| Research Design | 2 | 2014 | 5987 | 0.050 |
Why?
|
| Chile | 1 | 2021 | 237 | 0.050 |
Why?
|
| Treatment Failure | 2 | 2012 | 2618 | 0.050 |
Why?
|
| Drug Resistance, Multiple | 1 | 2001 | 252 | 0.050 |
Why?
|
| Ebola Vaccines | 1 | 2020 | 24 | 0.050 |
Why?
|
| Antibiotic Prophylaxis | 2 | 2002 | 639 | 0.050 |
Why?
|
| DNA Fingerprinting | 1 | 2000 | 112 | 0.050 |
Why?
|
| Nipah Virus | 1 | 2019 | 8 | 0.050 |
Why?
|
| Disk Diffusion Antimicrobial Tests | 1 | 2019 | 9 | 0.050 |
Why?
|
| Pediculus | 1 | 1999 | 6 | 0.050 |
Why?
|
| Lice Infestations | 1 | 1999 | 8 | 0.040 |
Why?
|
| Microscopy | 1 | 2005 | 903 | 0.040 |
Why?
|
| Insecticide Resistance | 1 | 1999 | 20 | 0.040 |
Why?
|
| Electrophoresis, Agar Gel | 1 | 1999 | 212 | 0.040 |
Why?
|
| Merozoite Surface Protein 1 | 1 | 1999 | 38 | 0.040 |
Why?
|
| Genes, Protozoan | 1 | 1999 | 163 | 0.040 |
Why?
|
| Phenazines | 1 | 2019 | 58 | 0.040 |
Why?
|
| Gentian Violet | 1 | 2019 | 31 | 0.040 |
Why?
|
| Scalp Dermatoses | 1 | 1999 | 40 | 0.040 |
Why?
|
| Convalescence | 1 | 2019 | 105 | 0.040 |
Why?
|
| Stress, Psychological | 1 | 2014 | 4245 | 0.040 |
Why?
|
| Hepatitis Antibodies | 1 | 2019 | 73 | 0.040 |
Why?
|
| Bangladesh | 1 | 2021 | 687 | 0.040 |
Why?
|
| Blotting, Southern | 1 | 1999 | 803 | 0.040 |
Why?
|
| Child Nutrition Disorders | 1 | 2020 | 149 | 0.040 |
Why?
|
| Bacterial Typing Techniques | 1 | 2019 | 256 | 0.040 |
Why?
|
| Laboratory Proficiency Testing | 1 | 2018 | 19 | 0.040 |
Why?
|
| Infection Control | 2 | 2017 | 966 | 0.040 |
Why?
|
| Biomedical Research | 1 | 2014 | 3309 | 0.040 |
Why?
|
| Quinine | 1 | 2018 | 54 | 0.040 |
Why?
|
| Water Microbiology | 1 | 2019 | 117 | 0.040 |
Why?
|
| Africa South of the Sahara | 2 | 2012 | 724 | 0.040 |
Why?
|
| Water Purification | 1 | 2018 | 48 | 0.040 |
Why?
|
| Erythromycin | 1 | 2018 | 120 | 0.040 |
Why?
|
| Case Management | 2 | 2011 | 286 | 0.040 |
Why?
|
| Quality Control | 1 | 2001 | 841 | 0.040 |
Why?
|
| Urban Population | 2 | 2017 | 2021 | 0.040 |
Why?
|
| Patient Compliance | 2 | 2013 | 2684 | 0.040 |
Why?
|
| Prenatal Diagnosis | 2 | 2015 | 1236 | 0.040 |
Why?
|
| Health Care Costs | 4 | 2015 | 3209 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 4 | 2012 | 5391 | 0.040 |
Why?
|
| Hypoglycins | 1 | 2017 | 2 | 0.040 |
Why?
|
| Iron, Dietary | 1 | 2018 | 141 | 0.040 |
Why?
|
| Molecular Epidemiology | 1 | 1999 | 468 | 0.040 |
Why?
|
| Regression Analysis | 3 | 2014 | 6459 | 0.040 |
Why?
|
| Antigens, Protozoan | 1 | 1999 | 322 | 0.040 |
Why?
|
| Reference Standards | 1 | 2001 | 1025 | 0.040 |
Why?
|
| Lymphocyte Count | 1 | 2019 | 793 | 0.040 |
Why?
|
| Israel | 1 | 2000 | 796 | 0.040 |
Why?
|
| Occupational Diseases | 1 | 2005 | 1471 | 0.040 |
Why?
|
| Aftercare | 1 | 2023 | 866 | 0.040 |
Why?
|
| Severity of Illness Index | 5 | 2016 | 15540 | 0.040 |
Why?
|
| Bayes Theorem | 2 | 2018 | 2309 | 0.040 |
Why?
|
| Evidence-Based Medicine | 1 | 2009 | 3610 | 0.040 |
Why?
|
| Health Status | 1 | 2010 | 4034 | 0.040 |
Why?
|
| Acute Disease | 2 | 2019 | 7149 | 0.040 |
Why?
|
| Sexual Maturation | 1 | 2018 | 265 | 0.040 |
Why?
|
| Government | 1 | 2017 | 165 | 0.040 |
Why?
|
| Cohort Studies | 6 | 2015 | 40561 | 0.040 |
Why?
|
| Gravidity | 1 | 2016 | 51 | 0.040 |
Why?
|
| Interviews as Topic | 2 | 2014 | 2539 | 0.030 |
Why?
|
| Latvia | 2 | 2006 | 14 | 0.030 |
Why?
|
| Trichomonas Vaginitis | 1 | 2016 | 35 | 0.030 |
Why?
|
| Smoking | 1 | 2013 | 8987 | 0.030 |
Why?
|
| Pregnancy, Unwanted | 1 | 2015 | 26 | 0.030 |
Why?
|
| Meat | 1 | 2019 | 592 | 0.030 |
Why?
|
| Hepatitis Viruses | 1 | 2015 | 17 | 0.030 |
Why?
|
| Penicillins | 1 | 2018 | 380 | 0.030 |
Why?
|
| Child Welfare | 2 | 2015 | 523 | 0.030 |
Why?
|
| Quality of Health Care | 1 | 2011 | 4371 | 0.030 |
Why?
|
| Cyclopropanes | 1 | 2017 | 416 | 0.030 |
Why?
|
| Epidemiology | 1 | 2018 | 287 | 0.030 |
Why?
|
| Immunity, Humoral | 1 | 2019 | 598 | 0.030 |
Why?
|
| Hemorrhagic Fever, Ebola | 1 | 2020 | 428 | 0.030 |
Why?
|
| Longitudinal Studies | 3 | 2018 | 13989 | 0.030 |
Why?
|
| Hepatitis A | 1 | 2015 | 133 | 0.030 |
Why?
|
| Child, Orphaned | 1 | 2015 | 55 | 0.030 |
Why?
|
| Reproducibility of Results | 4 | 2016 | 19905 | 0.030 |
Why?
|
| Acquired Immunodeficiency Syndrome | 2 | 2014 | 2232 | 0.030 |
Why?
|
| Antibodies, Viral | 2 | 2019 | 3176 | 0.030 |
Why?
|
| Pregnancy in Adolescence | 1 | 2015 | 158 | 0.030 |
Why?
|
| Reproductive Health Services | 1 | 2015 | 80 | 0.030 |
Why?
|
| Hospitals | 2 | 2021 | 3952 | 0.030 |
Why?
|
| Protozoan Proteins | 1 | 1999 | 827 | 0.030 |
Why?
|
| Host-Parasite Interactions | 1 | 2016 | 295 | 0.030 |
Why?
|
| Glycine | 1 | 2017 | 671 | 0.030 |
Why?
|
| Ethambutol | 2 | 2005 | 60 | 0.030 |
Why?
|
| Health Facility Environment | 1 | 2013 | 34 | 0.030 |
Why?
|
| Cluster Analysis | 2 | 2011 | 2715 | 0.030 |
Why?
|
| Aerosols | 1 | 2016 | 625 | 0.030 |
Why?
|
| Cattle | 1 | 2019 | 3922 | 0.030 |
Why?
|
| Vomiting | 1 | 2016 | 636 | 0.030 |
Why?
|
| Praziquantel | 1 | 2012 | 25 | 0.030 |
Why?
|
| Community-Based Participatory Research | 1 | 2014 | 214 | 0.030 |
Why?
|
| Albendazole | 1 | 2012 | 33 | 0.030 |
Why?
|
| DNA Probes | 1 | 1994 | 560 | 0.030 |
Why?
|
| Mexico | 2 | 2005 | 690 | 0.030 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2017 | 459 | 0.030 |
Why?
|
| District of Columbia | 2 | 2002 | 157 | 0.030 |
Why?
|
| Health Personnel | 2 | 2018 | 3218 | 0.030 |
Why?
|
| Safe Sex | 1 | 2013 | 141 | 0.030 |
Why?
|
| Chlamydia Infections | 1 | 2016 | 365 | 0.030 |
Why?
|
| Antigens, Viral | 1 | 2016 | 1035 | 0.030 |
Why?
|
| South Africa | 2 | 2008 | 1731 | 0.030 |
Why?
|
| Soil | 1 | 2012 | 106 | 0.030 |
Why?
|
| False Negative Reactions | 1 | 2013 | 588 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2000 | 4933 | 0.030 |
Why?
|
| Kinetics | 1 | 2019 | 6473 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 2018 | 1782 | 0.030 |
Why?
|
| Gonorrhea | 1 | 2016 | 335 | 0.030 |
Why?
|
| Mathematical Computing | 1 | 2011 | 147 | 0.030 |
Why?
|
| Folic Acid | 1 | 2018 | 1300 | 0.020 |
Why?
|
| Bacteriological Techniques | 1 | 2012 | 277 | 0.020 |
Why?
|
| Proviruses | 1 | 2012 | 318 | 0.020 |
Why?
|
| Housing | 1 | 2016 | 664 | 0.020 |
Why?
|
| Health Education | 1 | 2017 | 1056 | 0.020 |
Why?
|
| Condoms | 1 | 2013 | 323 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2000 | 10943 | 0.020 |
Why?
|
| Algorithms | 1 | 2011 | 13881 | 0.020 |
Why?
|
| HIV-2 | 1 | 2011 | 167 | 0.020 |
Why?
|
| Space-Time Clustering | 1 | 2010 | 49 | 0.020 |
Why?
|
| Patient Discharge | 1 | 2023 | 3313 | 0.020 |
Why?
|
| Poisson Distribution | 1 | 2011 | 513 | 0.020 |
Why?
|
| Dehydration | 1 | 2011 | 234 | 0.020 |
Why?
|
| Attitude of Health Personnel | 2 | 2015 | 3843 | 0.020 |
Why?
|
| Meningitis | 1 | 2011 | 216 | 0.020 |
Why?
|
| Fees and Charges | 1 | 2011 | 195 | 0.020 |
Why?
|
| Health Services | 1 | 2015 | 758 | 0.020 |
Why?
|
| Health Care Reform | 1 | 1999 | 1261 | 0.020 |
Why?
|
| Culture | 1 | 2013 | 633 | 0.020 |
Why?
|
| Species Specificity | 1 | 1994 | 2478 | 0.020 |
Why?
|
| Sample Size | 1 | 2013 | 845 | 0.020 |
Why?
|
| Databases, Factual | 2 | 2014 | 7729 | 0.020 |
Why?
|
| DNA Primers | 1 | 1994 | 2892 | 0.020 |
Why?
|
| Prisoners | 1 | 2012 | 297 | 0.020 |
Why?
|
| Genome, Viral | 1 | 2012 | 667 | 0.020 |
Why?
|
| Peru | 1 | 2012 | 881 | 0.020 |
Why?
|
| Cardiovascular Diseases | 1 | 2014 | 15165 | 0.020 |
Why?
|
| Health Policy | 2 | 2017 | 2661 | 0.020 |
Why?
|
| Cough | 1 | 2012 | 555 | 0.020 |
Why?
|
| Respiratory Tract Infections | 2 | 2008 | 961 | 0.020 |
Why?
|
| Computers, Handheld | 1 | 2010 | 208 | 0.020 |
Why?
|
| Metabolic Diseases | 1 | 2014 | 658 | 0.020 |
Why?
|
| Rifamycins | 1 | 2007 | 25 | 0.020 |
Why?
|
| Guideline Adherence | 1 | 2018 | 2266 | 0.020 |
Why?
|
| Drug Resistance, Viral | 1 | 2012 | 820 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 2019 | 4560 | 0.020 |
Why?
|
| Gender Identity | 1 | 2013 | 688 | 0.020 |
Why?
|
| Hypoglycemia | 1 | 2015 | 861 | 0.020 |
Why?
|
| Survival Rate | 2 | 2016 | 12788 | 0.020 |
Why?
|
| Malabsorption Syndromes | 1 | 2007 | 135 | 0.020 |
Why?
|
| Lung | 1 | 2005 | 9856 | 0.020 |
Why?
|
| Immunoglobulin A | 1 | 2010 | 992 | 0.020 |
Why?
|
| DNA-Directed RNA Polymerases | 1 | 2009 | 371 | 0.020 |
Why?
|
| Professional Practice | 1 | 2008 | 326 | 0.020 |
Why?
|
| Arizona | 1 | 2006 | 108 | 0.020 |
Why?
|
| Outpatients | 1 | 2014 | 1486 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2019 | 4479 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2011 | 2971 | 0.020 |
Why?
|
| Financing, Organized | 1 | 2007 | 202 | 0.020 |
Why?
|
| Neoplasms | 1 | 2014 | 21683 | 0.020 |
Why?
|
| Lithuania | 1 | 2005 | 13 | 0.020 |
Why?
|
| Likelihood Functions | 1 | 2009 | 1005 | 0.020 |
Why?
|
| Streptomycin | 1 | 2005 | 69 | 0.020 |
Why?
|
| Social Support | 1 | 2015 | 2118 | 0.020 |
Why?
|
| Hypoglycemic Agents | 1 | 2017 | 2872 | 0.020 |
Why?
|
| Virus Replication | 1 | 2012 | 2534 | 0.020 |
Why?
|
| Pregnancy Outcome | 1 | 2015 | 2795 | 0.020 |
Why?
|
| Fever | 1 | 2012 | 1616 | 0.020 |
Why?
|
| Lung Diseases | 1 | 2014 | 1886 | 0.020 |
Why?
|
| Adaptation, Psychological | 1 | 2015 | 2576 | 0.020 |
Why?
|
| Seroepidemiologic Studies | 1 | 2005 | 401 | 0.020 |
Why?
|
| Interinstitutional Relations | 1 | 2005 | 241 | 0.010 |
Why?
|
| Causality | 1 | 2011 | 1275 | 0.010 |
Why?
|
| Pneumonia | 1 | 2016 | 2133 | 0.010 |
Why?
|
| Investments | 1 | 2005 | 143 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 3870 | 0.010 |
Why?
|
| Viral Load | 1 | 2012 | 3299 | 0.010 |
Why?
|
| Kidney Diseases | 1 | 2014 | 2149 | 0.010 |
Why?
|
| Haiti | 1 | 2005 | 553 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2011 | 5179 | 0.010 |
Why?
|
| Russia | 1 | 2004 | 408 | 0.010 |
Why?
|
| Breast Feeding | 1 | 2011 | 1338 | 0.010 |
Why?
|
| Health Care Surveys | 1 | 2010 | 2453 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2008 | 2886 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2019 | 9959 | 0.010 |
Why?
|
| Base Sequence | 1 | 1994 | 12797 | 0.010 |
Why?
|
| Drug Utilization | 1 | 2008 | 1183 | 0.010 |
Why?
|
| Skin Diseases, Infectious | 1 | 2002 | 74 | 0.010 |
Why?
|
| Inpatients | 1 | 2014 | 2518 | 0.010 |
Why?
|
| Health Promotion | 1 | 2014 | 2205 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2008 | 3508 | 0.010 |
Why?
|
| Markov Chains | 1 | 2005 | 969 | 0.010 |
Why?
|
| Americas | 1 | 2001 | 111 | 0.010 |
Why?
|
| Infant Welfare | 1 | 2001 | 81 | 0.010 |
Why?
|
| Costs and Cost Analysis | 1 | 2007 | 1681 | 0.010 |
Why?
|
| Hospitals, General | 1 | 2005 | 749 | 0.010 |
Why?
|
| Models, Economic | 1 | 2005 | 713 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 1994 | 18111 | 0.010 |
Why?
|
| Parents | 1 | 2014 | 3407 | 0.010 |
Why?
|
| Sex Distribution | 1 | 2006 | 2297 | 0.010 |
Why?
|
| Serologic Tests | 1 | 2002 | 374 | 0.010 |
Why?
|
| Communication | 1 | 2014 | 3749 | 0.010 |
Why?
|
| Probability | 1 | 2006 | 2505 | 0.010 |
Why?
|
| Random Allocation | 1 | 2005 | 2429 | 0.010 |
Why?
|
| Borneo | 1 | 1999 | 2 | 0.010 |
Why?
|
| Idaho | 1 | 1999 | 16 | 0.010 |
Why?
|
| Cost Savings | 1 | 2005 | 926 | 0.010 |
Why?
|
| Permethrin | 1 | 1999 | 16 | 0.010 |
Why?
|
| Botswana | 1 | 2002 | 1040 | 0.010 |
Why?
|
| Decision Making | 1 | 2013 | 3887 | 0.010 |
Why?
|
| Drug Prescriptions | 1 | 2008 | 1637 | 0.010 |
Why?
|
| Radiography, Thoracic | 1 | 2005 | 1265 | 0.010 |
Why?
|
| Seizures | 1 | 2011 | 2859 | 0.010 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2007 | 1873 | 0.010 |
Why?
|
| Organizations | 1 | 1999 | 170 | 0.010 |
Why?
|
| Health Care Sector | 1 | 1999 | 194 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2006 | 6365 | 0.010 |
Why?
|
| Ambulatory Care | 1 | 2008 | 2708 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2012 | 12959 | 0.010 |
Why?
|
| Mutation | 2 | 2012 | 29786 | 0.010 |
Why?
|
| Comorbidity | 1 | 2011 | 10388 | 0.010 |
Why?
|
| Environmental Monitoring | 1 | 2002 | 1414 | 0.010 |
Why?
|
| Bacterial Proteins | 1 | 2009 | 3848 | 0.010 |
Why?
|
| Decision Support Techniques | 1 | 2005 | 1956 | 0.010 |
Why?
|
| Policy Making | 1 | 1999 | 554 | 0.010 |
Why?
|
| Phenotype | 1 | 2012 | 16365 | 0.010 |
Why?
|
| Europe | 1 | 2001 | 3339 | 0.010 |
Why?
|
| Obesity | 1 | 2017 | 12745 | 0.010 |
Why?
|
| Liver | 1 | 2008 | 7474 | 0.010 |
Why?
|
| Massachusetts | 1 | 1999 | 8663 | 0.000 |
Why?
|
| Models, Biological | 1 | 1999 | 9583 | 0.000 |
Why?
|